nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”nodgo-355Research ArticleПРОБЛЕМЫ XXI ВЕКАTHE PROBLEMS OF THE 21 ST CENTURYДозировка противоопухолевых препаратов у детей первого года жизни: современный подход и рекомендации рабочей группы по стандартизации химиотерапии Детской онкологической группыChildren’s Oncology Group Chemotherapy Standardization Task ForceБалисФ. М.BalisF. M.

Department of Pediatrics 

Philadelphia, Pennsylvania

balisf@email.chop.eduВомерР. Б.WomerR. B.

Department of Pediatrics 

Philadelphia, Pennsylvania

БергС.BergS.

Department of Pediatrics 

Houston, Texas

ВиникН.WinickN.

Department of Pediatrics 

Dallas, Texas

АдамсонП. С.AdamsonP. C.

Department of Pediatrics 

Philadelphia, Pennsylvania

ФоксЭ.FoxE.

Department of Pediatrics 

Philadelphia, Pennsylvania

Детская больница ФиладельфииСоединённые Штаты АмерикиThe Children’s Hospital of PhiladelphiaUnited StatesТехасский детский онкологический центрСоединённые Штаты АмерикиTexas Children’s Cancer CenterUnited StatesЮго-Западный Медицинский центр Техасского университетаСоединённые Штаты АмерикиUniversity of Texas SouthwesternUnited States201819022018511116Copyright © Балис Ф.М., Вомер Р.Б., Берг С., Виник Н., Адамсон П.С., Фокс Э., 20182018Балис Ф.М., Вомер Р.Б., Берг С., Виник Н., Адамсон П.С., Фокс Э.Balis F.M., Womer R.B., Berg S., Winick N., Adamson P.C., Fox E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/355

Анализ методов модификации доз химиопрепаратов у детей первого года жизни, используемых в 29 протоколах Детской онкологической группы (Children’s Oncology Group, COG) по 10 типам опухолей, выявил 11 групп параметров для оценки детей первого года жизни, таких как возраст, вес, площадь поверхности тела (ППТ) или комбинации этих параметров, и 8 разных методов модификации доз. Новый метод дозирования противоопухолевых препаратов был разработан на основании того, что проанализированные методы модификации доз были созданы в целях снижения токсичности, которая не зависит от типа опухоли. Новый метод предлагает применять таблицы доз, сгруппированных на основании ППТ, для детей первого года жизни и детей с ППТ < 0,6 м2 с постепенным переходом с доз, основанных на массе тела, на дозы, основанные на ППТ.

An analysis of dose modifications for infants in 29 Children’s Oncology Group protocols across 10 cancer types revealed 11 sets of criteria defining the infant population using age, weight, body surface area (BSA), or a combination of these parameters and eight dose modification methods. A new method of dosing anticancer drugs in infants was developed based on the rationale that prior modifications were implemented to reduce toxicity, which is not cancer-specific. The new method uses BSA dose banding in dosing tables for infants and children with a BSA < 0.6 m2 and gradually transitions from body weight based to BSA-based dosing. 

противоопухолевые препаратыплощадь поверхности теладозадети первого года жизниanticancer drugsbody surface areadoseinfantsГрант U10CA180886 и фонд Святого БалдрикаReferencesGurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996;14(9):2590–11.Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996;14(9):2590–11.Goldsmith M.A., Slavik M., Carter S.K. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res 1975;35(5):1354–64.Goldsmith M.A., Slavik M., Carter S.K. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res 1975;35(5):1354–64.Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958;18(7):853–6.Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958;18(7):853–6.Baker S.D., Verweij J., Rowinsky E.K. et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991– 2001. J Natl Cancer Inst 2002;94(24):1883–8.Baker S.D., Verweij J., Rowinsky E.K. et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991– 2001. J Natl Cancer Inst 2002;94(24):1883–8.Ratain M.J. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 1998;16(7):2297–8.Ratain M.J. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 1998;16(7):2297–8.Felici A., Verweij J., Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 2002;38(13):1677–84.Felici A., Verweij J., Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 2002;38(13):1677–84.Chatelut E., Puisset F. The scientific basis of body surface area-based dosing. Clin Pharmacol Ther 2014;95(4):359–61.Chatelut E., Puisset F. The scientific basis of body surface area-based dosing. Clin Pharmacol Ther 2014;95(4):359–61.Chatelut E., White-Koning M.L., Mathijssen R.H. et al. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer 2012;107(7):1100–6.Chatelut E., White-Koning M.L., Mathijssen R.H. et al. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer 2012;107(7):1100–6.Coppoletta J.M., Wolbach S.B. Body length and organ weights of infants and children. Am J Pathol 1932;9:55–70.Coppoletta J.M., Wolbach S.B. Body length and organ weights of infants and children. Am J Pathol 1932;9:55–70.Bagatell R., Herzog C.E., Trippett T.M. et al. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res 2011;17(3):611–9.Bagatell R., Herzog C.E., Trippett T.M. et al. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res 2011;17(3):611–9.Fox E., Maris J.M., Cohn S.L. et al. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother Pharmacol 2010;66(4):737–43.Fox E., Maris J.M., Cohn S.L. et al. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother Pharmacol 2010;66(4):737–43.Kanamori M., Takahashi H., Echizen H. Developmental changes in the liver weight-and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children. Int J Clin Pharmacol Ther 2002;40(11):485–92.Kanamori M., Takahashi H., Echizen H. Developmental changes in the liver weight-and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children. Int J Clin Pharmacol Ther 2002;40(11):485–92.Morgan E., Baum E., Breslow N., Takashima J., D’Angio G. Chemotherapy related toxicity in infants treated according to the Second National Wilms’ Tumor Study. J Clin Oncol 1988;6(1):51–5.Morgan E., Baum E., Breslow N., Takashima J., D’Angio G. Chemotherapy related toxicity in infants treated according to the Second National Wilms’ Tumor Study. J Clin Oncol 1988;6(1):51–5.Woods W.G., O’Leary M., Nesbit M.E. Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia. J Pediatr 1981;98(4):642–5.Woods W.G., O’Leary M., Nesbit M.E. Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia. J Pediatr 1981;98(4):642–5.Aperia A., Broberger O., Thodenius K., Zetterstrom R. Development of renal control of salt and fluid homeostasis during the first year of life. Acta Paediatr 1975;64(3):393–8.Aperia A., Broberger O., Thodenius K., Zetterstrom R. Development of renal control of salt and fluid homeostasis during the first year of life. Acta Paediatr 1975;64(3):393–8.Guignard J.P., Torrado A., Da Cunha O., Gautier E. Glomerular filtration rate in the first three weeks of life. J Pediatr 1975;87(2):268–72.Guignard J.P., Torrado A., Da Cunha O., Gautier E. Glomerular filtration rate in the first three weeks of life. J Pediatr 1975;87(2):268–72.Kearns G.L. Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes? Curr Opin Pediatr 1995;7(2):220–33.Kearns G.L. Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes? Curr Opin Pediatr 1995;7(2):220–33.Cresteil T. Onset of xenobiotic metabolism in children: toxicological implications. Food Addit Contam 1998;15(Suppl):45–51.Cresteil T. Onset of xenobiotic metabolism in children: toxicological implications. Food Addit Contam 1998;15(Suppl):45–51.Upreti V.V., Wahlstrom J.L. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol 2016;56:266–83.Upreti V.V., Wahlstrom J.L. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol 2016;56:266–83.Langholz B., Skolnik J.M., Barrett J.S. et al. Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children’s Oncology Group. Pediatr Blood Cancer 2011;57(2):252–7.Langholz B., Skolnik J.M., Barrett J.S. et al. Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children’s Oncology Group. Pediatr Blood Cancer 2011;57(2):252–7.

The authors declare that there are no conflicts of interest present.